The goal of the study is to evaluate progression free survival between the Therapy per Physician Choice (TPC) versus Sacituzumab + Pembrolizumab regimen. Follow-up period of 5 years from the date of randomization.
Contact phone
(517) 364-2835
Contact email
[email protected]
Principal investigator
Dr. Srkalovic, MD, PhD
Trial Category
Cancer
Trial SubCategory
Bladder - Urothelial
Webform